<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130777</url>
  </required_header>
  <id_info>
    <org_study_id>2016-04</org_study_id>
    <nct_id>NCT03130777</nct_id>
  </id_info>
  <brief_title>ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent</brief_title>
  <official_title>Multicenter Study of Congenital Pulmonic Valve Dysfunction Studying the SAPIEN 3 THV With the Alterra Adaptive Prestent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the safety and effectiveness of the Edwards Alterra Adaptive Prestent in&#xD;
      conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with&#xD;
      a dysfunctional right ventricular outflow tract/pulmonary valve (RVOT/PV) who are indicated&#xD;
      for treatment of pulmonary regurgitation (PR).&#xD;
&#xD;
      Following completion of enrollment, subjects will be eligible for enrollment in the continued&#xD;
      access phase of the trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2017</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, prospective, multi-center study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Main Cohort: THV Dysfunction</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as a non-hierarchical composite of:&#xD;
RVOT/PV Reintervention&#xD;
Moderate or greater total Pulmonic Regurgitation via Transthoracic Echocardiography (TTE)&#xD;
Mean RVOT/PV Gradient &gt;= 35mmHg via TTE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PDS Registry: Acute PDS Success</measure>
    <time_frame>24 hours</time_frame>
    <description>Defined as a non-hierarchical composite of:&#xD;
Single THV implanted in the desired location&#xD;
Right ventricle to pulmonary artery (RV-PA) peak-to-peak gradient &lt; 35 mmHg post-THV implantation&#xD;
Less than moderate total pulmonary regurgitation by discharge TTE (or earliest evaluable TTE)&#xD;
Free of SAPIEN 3 / Alterra explant at 24 hours post-implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Main Cohort: Improvement in Total Pulmonary Regurgitation from Baseline</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Pulmonary Disease</condition>
  <condition>Transcatheter Pulmonary Valve Replacement (TPVR)</condition>
  <condition>Tetralogy of Fallot</condition>
  <condition>Congenital Heart Disease</condition>
  <condition>Pulmonary Regurgitation</condition>
  <arm_group>
    <arm_group_label>TPVR - Main Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Commander Delivery System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPVR - PDS Registry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Pulmonic Delivery System (PDS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards Alterra Adaptive Prestent with SAPIEN 3 THV</intervention_name>
    <description>The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.</description>
    <arm_group_label>TPVR - Main Cohort</arm_group_label>
    <arm_group_label>TPVR - PDS Registry</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The candidate/candidate's legally authorized representative has been informed of the&#xD;
             nature of the study, agrees to its provisions and has provided written informed&#xD;
             consent.&#xD;
&#xD;
          2. Weight is ≥ 20 kg (44 lbs).&#xD;
&#xD;
          3. RVOT/PV with moderate or greater PR by TTE.&#xD;
&#xD;
          4. RVOT/PV proximal and distal landing zone diameter ≥ 27 mm and ≤ 38 mm, and minimum of&#xD;
             35 mm from contractile tissue to lowest pulmonary artery takeoff.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active infection requiring current antibiotic therapy (if temporary illness, patient&#xD;
             may be a candidate 2 weeks after discontinuation of antibiotics).&#xD;
&#xD;
          2. History of or active endocarditis (active treatment with antibiotics) within the past&#xD;
             180 days.&#xD;
&#xD;
          3. Leukopenia (WBC &lt; 2000 cells/μL), anemia (Hgb &lt; 7 g/dL), thrombocytopenia (platelets &lt;&#xD;
             50,000 cells/μL) or any known blood clotting disorder.&#xD;
&#xD;
          4. Inappropriate anatomy for introduction and delivery of the Alterra Adaptive Prestent&#xD;
             or the SAPIEN 3 THV.&#xD;
&#xD;
          5. Need for concomitant atrial septal defect or ventricular septal defect closure or&#xD;
             other concomitant interventional procedures other than pulmonary artery or branch&#xD;
             pulmonary artery stenting or angioplasty&#xD;
&#xD;
          6. Interventional/surgical procedures within 30 days prior to the Alterra or valve&#xD;
             implant procedure&#xD;
&#xD;
          7. Any planned surgical, percutaneous coronary or peripheral procedure to be performed&#xD;
             within the 30 day follow-up from the Alterra or valve implant procedure&#xD;
&#xD;
          8. History of or current intravenous drug use&#xD;
&#xD;
          9. Major or progressive non-cardiac disease resulting in a life expectancy of less than&#xD;
             one year&#xD;
&#xD;
         10. Known hypersensitivity to aspirin or heparin and cannot be treated with other&#xD;
             antiplatelet and/or antithrombotic medications&#xD;
&#xD;
         11. Known hypersensitivity to nitinol, cobalt-chromium, nickel or contrast media that&#xD;
             cannot be adequately pre-medicated&#xD;
&#xD;
         12. Currently participating in an investigational drug or another device study [Note:&#xD;
             Trials requiring extended follow up for products that were investigational, but have&#xD;
             since become commercially available, are not considered investigational devices.]&#xD;
&#xD;
         13. Positive urine or serum pregnancy test in female patients of child-bearing potential&#xD;
&#xD;
         14. Renal insufficiency (creatinine &gt; 3.0 mg/dL) and/or renal replacement therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Zahn, MD, FACC, FSCAI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edwards THV Clinical Affairs</last_name>
    <phone>(949) 250-2500</phone>
    <email>THV_CT.gov@edwards.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University/ Children's Healthcare of Atlanta (CHOA)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Health Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virgina</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

